Jake Becraft, CEO of Strand Therapeutics, shared a powerful story on The Tim Ferriss Show: a patient with stage 4 melanoma, given months to live, achieved a complete recovery thanks to Strand's RNA therapy and the abscopal effect. It was a clear, undeniable win for medicine, demonstrating what Becraft calls a “good drug.” But here's the kicker for ambitious founders in their 20s and 30s: a “good drug” isn't the same thing as a “good product,” and mistaking the two will kill your company's potential for wide impact. Becraft argues too many breakthroughs remain niche because they don't solve the core challenge of scalable, affordable delivery.

The "Good Drug" Trap

A good drug, as Becraft puts it, “can someone take this and it does something like injecting a therapy into someone in a way that is very hard to replicate but did a great thing for that individual person is a good drug fundamentally. It is a good drug. It helped that person.” Think of ex vivo cell therapies: they work. They can save lives. But at a manufacturing cost of $750,000 and taking three months to produce each dose, they are logistically impossible to scale. “It's very hard to see a world in which that drug has a large impact on the patient population because of the the fundamental cost, the cogs, the cost of goods sold, not biotech, just straight business. The cost of doing it and the time it takes to get it to people, that's a bad product,” Becraft explains.

Designing for Impact: The "Good Product" Imperative

Becraft's core insight is that for true population-level change, a therapy must be a “good product.” This means designing it to be effectively and affordably delivered to a large patient population. It’s about fitting into the existing healthcare infrastructure, much like Amazon perfected logistics or SpaceX made rockets reusable. Strand Therapeutics, for example, develops in vivo cell therapy to reprogram cells directly inside the body. This avoids the high costs and time delays of external manufacturing. As Becraft states, “If you want to have the largest impact in medicine, you need to make medicines that plug into existing infrastructure.” The science is only half the battle; the delivery mechanism is the other.

Key Takeaways

  • A drug can be incredibly effective for an individual (a “good drug”) but fail to impact population health because it’s too costly or complex to deliver broadly (a “bad product”).
  • Existing ex vivo cell therapies, while life-saving, exemplify “bad products” due to manufacturing costs of $750,000 and three-month production times, making them unscalable.
  • For maximum impact, biotech innovation must integrate with current healthcare infrastructure, like developing in vivo therapies that avoid complex external processing.
  • Companies aiming for widespread patient benefit should prioritize scalability, cost of goods sold (COGS), and delivery methods from the earliest stages of development.
  • This vital distinction is captured in Jake Becraft's framework: The Good Drug vs. Good Product Rule.

The Good Drug vs. Good Product Rule

  • Good Drug: Can someone take this and it does something like injecting a therapy into someone in a way that is very hard to replicate but did a great thing for that individual person is a good drug fundamentally. It is a good drug. It helped that person.
  • Good Product: Much more this is where the idea of how we get medicines to people come into come into play. A good product is designed to be effectively and affordably delivered to a large patient population, integrating with existing infrastructure (e.g., outpatient IV instead of complex, costly manufacturing).

When This Works (and When It Doesn't)

Jake Becraft says this framework applies when evaluating a therapeutic's real-world impact and scalability. A 'good drug' helps an individual, but a 'good product' ensures widespread access and changes population-level health, especially by plugging into existing medical infrastructure rather than requiring entirely new systems. This rule shines when your ambition extends beyond a handful of patients to truly transform public health. If you're building a biotech company for patient impact, not just scientific validation, this rule forces a critical lens on every development decision.

However, the framework isn't a universal solution. For ultra-rare diseases, where patient populations are tiny and treatment options non-existent, even a "bad product" by this definition (expensive, hard to administer) might be celebrated as a miracle drug. Similarly, in very early-stage research, the singular focus must be on proving efficacy, even if productization feels miles away. But for founders aiming for mass-market therapeutics or a platform that touches millions, pushing past the "good drug" hurdle to build a "good product" is a make-or-break challenge.

What to Do With This

If you're building a biotech startup, don't wait for phase 3 trials to ask the product question. This week, pick your lead therapeutic candidate. Map out its ideal delivery to 100,000 patients. Where do the costs (like the $750,000 ex vivo cell therapy example) or logistical bottlenecks (like the 3-month manufacturing time) crush scalability? Can you redesign the delivery, the manufacturing, or even the underlying mechanism (like Becraft's in vivo cell therapy) to integrate into existing infrastructure, making it an outpatient procedure or a lower-cost, faster-produced option? This isn't just about science; it's about business model and market fit from day one.